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inﬂammatory drug (NSAID) (meloxicam). For each cohort, use
of prescription analgesics was tracked pre-withdrawal (January-
September 2004) and post-withdrawal (2005–2006). The impact
of the withdrawal on drug utilization by former rofecoxib users
was assessed by comparing changes in their drug consumption
with that of celecoxib or meloxicam users during the same time
period. RESULTS: The study cohorts included: 29,438 rofe-
coxib, 34,937 celecoxib, and 7131 meloxicam users. The groups
were demographically similar, except for a higher proportion of
women in the meloxicam cohort. In 2005, former rofecoxib users
primarily substituted other COX-2 inhibitors (22% celecoxib,
10% valdecoxib) or non-selective NSAIDS (which increased to
48% from 14% pre-withdrawal). There was no substantial
change in use of opioid /other analgesics. The percentage of
former rofecoxib users continuing to receive any prescription
analgesic was 83% (2005) and 77% (2006). By comparison,
overall utilization of celecoxib and meloxicam declined to 87%
and 91% respectively in 2005 and 80% and 84% respectively in
2006. By 2006, 59% of celecoxib users and 53% of meloxicam
users had discontinued these medications. CONCLUSION: By
2006, the proportion of former rofecoxib users who had discon-
tinued prescription analgesics altogether was substantially higher
than among patients who not previously receiving a COX-2
inhibitor. This suggests the potential harm from unsafe drugs
may not be limited to side effects, but also includes the disruption
of care due to withdrawal of effective treatment.
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OBJECTIVE: Abatacept is a new biological DMARD with selec-
tive co-stimulation modulator mechanism of action that was
recently approved in Brazil for the treatment of patients with
moderate to severe RA. We aim to evaluate and describe the
budget impact of the inclusion of abatacept in the National
Program of Exceptional Medications (NPEM) with the tumor
necrosis factor (TNF) antagonists currently in use and included.
METHODS: Using data provided by Brazilian Ministry of
Health, our study estimates the cost associated with the inclusion
of Abatacept for inadequate responders to methotrexate and
TNF antagonists compared with actual scenario (without Abata-
cept). Our model presumes: adequate doses and regimen of
abatacept (10 mg/kg. 0, 2, 4, and each 4 weeks), inﬂiximab
(4.2 mg/kg each dose of inﬂiximab, 0, 2, 6, and each 8 weeks),
etanercept (25 mg each dose/twice a week) and adalimumab
(40 mg each dose, twice a month), and we accept the actual
distribution of TNF antagonists used by NPEM (with adoption
of 20% of increase in the number of the RA patients each
year—NPEM data). According to literature, 30% of the patients
with inadequate response to methotrexate will be eligible to use
abatacept, and we accept this percentage to introduce patients in
the abatacept group. The initial population is 4978 patients
currently in use of TNF antagonists in 2007. RESULTS: In the
ﬁrst year of inclusion there is an increase in costs of R$3,085,711
(US$1,763,263). In the second and third years there are signiﬁ-
cant savings on budgets, R$97,593,971 (US$55,767,983) and
R$129,458,357 (US$73,976,204), respectively. CONCLUSION:
The incorporation of abatacept into the NPEM is cost-saving to
the Brazilian Public Health System, saving R$129,458,357.00
(US$73,976,204) after the third year.
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OBJECTIVE: To conduct a cost-beneﬁt analysis to compare the
hypothetical introduction of a new intervention, internal ﬁxation
(IF), with hemiarthroplasty (HA) for the treatment of displaced
femoral neck fractures in patients greater than 60 years old.
METHODS: We estimated the costs from a third party payer
perspective after one year of two strategies (HA and IF) for the
treatment of femoral neck fractures in patients over the age of 60.
Using a decision board, we elicited patient preferences for the
two operative approaches and calculated the net beneﬁt using the
willingness-to-pay technique. RESULTS: The 1-year projected
cost of one IF was $18,100 and that of one HA was $15,843
(incremental cost of $2,257 for each IF). Of 108 participants, 61
(56.5%) chose IF as the preferred treatment option and were
willing to pay an average of $3.33 per month to have this option
available if needed. In Ontario, the total incremental cost of
performing IF in patients that choose it was $64,714,103, and
the total societal beneﬁt was $289,263,600, yielding a net beneﬁt
of $224,549,497. CONCLUSION: The beneﬁts of IF over HA
outweigh the incremental costs from the perspective of a third
party payer. Therefore, IF should be available to patients that
choose it.
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OBJECTIVE: Total hip arthroplasty (THA) is a common and
successful procedure with nearly 250,000 primary arthroplasties
performed yearly in the United States. This number is estimated
to increase by at least 5% annually over the next decade. The
resulting growth in health care utilization and costs maybe offset
by innovative implant technologies with increased survivorship.
This study quantiﬁes the economic cost savings to payers
from improved survivorship. METHODS: A simulation model
is developed to estimate the long-term cost implications of
improvements in THA survivorship. The model considers costs
associated with all primary hip replacements performed in the
United States over a ten-year horizon. The analysis draws upon
the literature to obtain information on long-term revision rates
for hip replacement surgeries. Inpatient treatment costs associ-
ated with THA and incidence and costs of the major complica-
tions, deep vein thrombosis and infection are included in the
model. RESULTS: Improved implant survivorship in THA is
estimated to save $1.6 billion over a ten-year horizon. The ma-
jority of these savings accrues from lower revision rates ($1.3
billion) with fewer complications accounting for $300 million in
additional savings. Sensitivity analyses reveal that cost savings
varied by survivorship ($1.1 to $2.0 billion) and hospital cost for
revision surgery ($1.3 to $3.1 billion). Other variations by phy-
sician costs, complications costs and discount rates are less pro-
nounced. However, under every scenario, costs savings are in
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excess of $1 billion. CONCLUSION: The economic value of
newer technologies with longer term survivorship will play an
important role in meeting the growing demand and ﬁnancial
burden of THA. Improved THA survivorship will also enhance
patients’ quality of life. Therefore, the longevity of these innova-
tive implants will be an important factor in evidence based deci-
sion making and economic evaluation of THA.
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OBJECTIVE: To estimate the life-time cost-effectiveness (CE) of
abatacept in patients with active RA and inadequate response to
MTX or anti-TNFs. METHODS: We developed a patient-level
simulation model to depict progression of functional disability
over time. Functional disability was expressed in terms of the
Health Assessment Questionnaire Disability Index (HAQ-DI).
Health-state utilities and medical-care costs were assumed to
depend on HAQ DI scores. The model separately estimated CE
using data from three phase III clinical trials: 1) abatacept in
patients with inadequate response to MTX (AIM); 2) abatacept
in patients with inadequate response to anti-TNFs (ATTAIN);
and 3) abatacept or inﬂiximab in patients with inadequate
response to MTX (BMS-IM101043). Cost-effectiveness of abata-
cept was examined in terms of the incremental cost (2006 Cana-
dian dollars) per quality-adjusted life-year (QALY). RESULTS: 1)
AIM trial: On a lifetime basis, abatacept was estimated to yield
an average of 1.4 additional QALYs per patient vs. MTX at a
mean incremental cost of $54,331; the estimated CE of abatacept
was $39,604 (95% CI: $38,746, $41,384) per QALY gained; 2)
ATTAIN: abatacept yielded an average of 1.2 additional QALY
vs. oral DMARDs alone at a mean incremental cost of $50,141;
estimated CE of abatacept was $42,021 (95% CI: $40,954,
$43,256) per QALY; 3) trial 043: Relative to placebo, abatacept
yielded an average of 1.58 additional QALY at a mean incremen-
tal cost of $58,351; incremental CE of abatacept was $37,094
($35,535, $38,727) per QALY; inﬂiximab yielded an average of
1.24 additional QALY at a mean incremental cost of $53,305;
incremental CE of inﬂiximab was $43,247 ($40,845, $44,587)
per QALY. Relative to inﬂiximab, the incremental CE of abata-
cept was about $14,841 per QALY. CONCLUSION: Abatacept
is cost-effective in patients with active RA and inadequate
response to DMARD or anti-TNF therapy and also highly cost
effective relative to inﬂiximab.
PMS10
THE COST-EFFECTIVENESS OF ABATACEPTVERSUS
RITUXIMAB IN PATIENTSWITH RHEUMATOID ARTHRITIS:A
PERSPECTIVE OFTHE CANADIAN PUBLICLY FUNDED
HEALTH CARE SYSTEM
Yuan Y1, Maier-Moldovan M2, Maclean R3, L’Italien GJ4
1Bristol Myers Squibb, Princeton, NJ, USA, 2Bristol-Myers Squibb,
Saint-Laurent, QC, Canada, 3Bristol-Myers Squibb Pharmaceuticals,
Lawrenceville, NJ, USA, 4Bristol Myers Squibb,Wallingford, CT, USA
OBJECTIVE: To estimate the life-time cost-effectiveness of
abatacept relative to rituximab in patients with active rheuma-
toid arthritis (RA) and an inadequate response to anti-tumor
necrosis factor (anti-TNF) therapy. METHODS: We used a pre-
viously published patient level simulation model to depict pro-
gression of functional disability over time in people with active
RA. Health-state utilities and medical-care costs were projected
based on the Health Assessment Questionnaire Disability Index
(HAQ-DI) scores. RA patients who were inadequate responders
to anti-TNF therapy were assumed to receive abatacept or ritux-
imab in combination with MTX on a lifelong basis or until
therapy discontinuation due to lack of efﬁcacy or side effects.
HAQ-DI improvement at 6 months (-25% versus -22%), after
adjustments for control drug response, were derived from two
comparable abatacept and rituximab Phase III trials. The cost of
abatacept (or rituximab) treatment was estimated at $18,480 (or
$20, 500) for the ﬁrst year, and at $17,160 (or $20,500) for
subsequent years. Costs and health effects were discounted at 5%
annually. All costs were expressed in 2007 Canadian Dollars.
First order and second order uncertainty were considered.
RESULTS: The reference case in the analysis is women aged
55–64 years. Relative to placebo, abatacept therapy was esti-
mated to yield an average of 1.07 (95% conﬁdence interval
[CI] = 1.00, 1.14) additional quality adjusted life years (QALY)
per patient, at a mean incremental cost of $45,875 (95%
CI = $42,795, $47,773); rituximab therapy was estimated to
yield an average of 0.94 (95% CI = 0.82, 1.05) additional QALY
per patient, at a mean incremental cost of $51,101 (95%
CI = $45,835, $57,175). Life time treatment with abatacept was
estimated to be a dominant strategy compared with rituximab,
primarily due to lower treatment costs and better HAQ improve-
ment. The study ﬁndings were robust under uncertainty analyses.
CONCLUSION: Abatacept therapy would be economically
attractive from a Canadian payer perspective.
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OBJECTIVE: The objective of this study was to access the cost-
effectiveness of rituximab (RTX) for the treatment of rheumatoid
arthritis (RA) in Taiwan from a payer’s (Bureau of National
Health Insurance [BNHI]) perspective. METHODS: A cost-
effectiveness model was developed to simulate the long-term
clinical outcome and cost impact for a cohort of 10,000 RA
patients over the lifetime. The main comparator was current
treatment arm, which included etanercept +methotrexate
(ETAN + MTX), adalimumab (ADAL) + MTX, leﬂunomide
(LEFT) + MTX, and cyclosporine. Relative clinical effectiveness
were estimated by an indirect comparison of published ACR
response rates adjusting for different study populations and
complemented with observational data. Quality adjusted life-
years (QALYs) were mapped from a disease severity measure
(Health Assessment Questionnaire [HAQ]) score. Average treat-
ment duration for biological agents, LFT + MTX, and CSA were
assumed to be 4.25, 4.10, and 1.70 years, respectively. Drug
acquisition costs were based on Taiwan’s National Health Insur-
ance fee schedule for 2007. Costs associated with drug adminis-
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